| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Compulsory License Tag | CL Tag Provision | Deal Date | R&D | Client | Licensee Category | Deal Source | Deal | Upfront Cash ($M) | Deal Size ($M) | Maximum Share (%) | Equity ($M) | Maximum Royalty (%) | Deal Type | Stage | Deal Subject | Exclusivity | Territory | Disease | Indication | Technology | Sub-Technology | Upfront Equity ($M) | Contingent Equity ($M) | R&D Support ($M) | FTE Rate ($M) | Loan ($M) | Dev / Reg Milestones ($M) | Other Milestones ($M) | Total Precommercial Payments ($M) | Sales Milestones ($M) | EFR$200M (%) | EFR$500M (%) | EFR$1B (%) | Marketing Fee (%) | Transfer Price (%) | Manufacture Cost + (%) | Profit Split (%) | Financial Term Explanations |
2 | Tag | Share equivalent to PS percentage; CL not a sublicensee & CL rev not included in Net Sales | 10/2020 | Atea Pharmaceuticals | Roche | Top Pharma | SEC Redacted | Deal | 350.00 | 1,000.00 | Co-Development, License | Phase II | AT-527 oral direct-acting antiviral to treat COVID-19 ex-US | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Infectious-Viral | Coronavirus | Synthetics | Small Molecule | 330.00 | 680.00 | 320.00 | low double-digit to mid-twenties royalties, per Atea's IPO prospectus | ||||||||||||||||
3 | Tag | Share equivalent to PS; CL rev not included in Net Sales | 7/2020 | Blueprint Medicines | Roche, Genentech | Major Biotech, Top Pharma | SEC Redacted | Deal | 675.00 | 1,702.00 | 50.00 | 100.00 | Co-Development, Co-Promotion, Equity, License, Option, Supply | Phase I | Pralsetinib RET inhibitor ex-China (co-exclusive rights in US), option to addt'l RET compound | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Cancer | Lung, Solid Tumors, Other Cancer | Synthetics | Small Molecule | 100.00 | 1,702.00 | 50.00 | $100M equity investment priced at $96.57 per share | High teen to mid-twenties royalties in ROW, per Blueprint's 6Q20 | $927M in agg milestones, per Blueprint's 6Q20 | 50% PS in US | ||||||||||||||
4 | Tag | Royalty reduced to CL rate | 7/2020 | Foghorn Therapeutics | Merck | Top Pharma | SEC Redacted | Deal | 15.00 | 425.00 | Co-Development, License, Research | Discovery | Gene Traffic Control platform to discover oncology therapeutics against transcription factor target | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Synthetics | Small Molecule | 245.00 | 260.00 | 165.00 | $165M per product, per Foghorn's IPO prospectus | mid-single digit to low teen royalties, per Foghorn's IPO prospectus | $245M per Foghorn's IPO prospectus | ||||||||||||||||
5 | Tag | Royalty reduced to CL rate | 5/2020 | Censa Pharmaceuticals | PTC Therapeutics | 2013-20 IPOs | SEC Redacted | Deal | 15.00 | 540.40 | 38.90 | Acquisition, CVR | Phase II, Orphan Indication | Acquisition for cash and shares | Exclusive | Worldwide | Endocrinological & Metabolic, Other/Miscellaneous | Genetic Disorders, Other Endocrinological & Metabolic | Synthetics | Small Molecule | 38.90 | 217.50 | 109.00 | 380.40 | 160.00 | $160M, per PTC's 6Q20 | 845K PTC shares, per PTC's 6Q20 | Single-digit to low double-digit royalties, per PTC's 6Q20 | $217.5M for two lead products, including $30M on completion of Ph III enrollment for PKU, per PTC's 6Q20 | $109M for add'l indications, per PTC's 6Q20 | |||||||||||||
6 | Tag | Share equivalent to PS; CL not a sublicensee | 3/2020 | Silence Therapeutics | AstraZeneca | Top Pharma | SEC Redacted | Deal | 60.00 | 2,080.00 | 20.00 | Co-Development, Equity, License, Option, Research | Discovery | RNAi therapeutics for cardio, renal, metabolic & respiratory diseases | Exclusive | Worldwide | Cardiovascular, Endocrinological & Metabolic, Renal, Respiratory | Broad Focus Cardiovascular, Broad Focus Endocrinological & Metabolic, Broad Focus Renal, Broad Focus Respiratory | Oligonucleotides | RNAi | 20.00 | 150.00 | 600.00 | 830.00 | 1,250.00 | $20M at signing, plus $40M by 1H21 | $250M/target | $20M for 4.2M shares, per Silence's IPO prospectus | high single-digit to low double-digit royalty, per Silence's IPO prospectus | $10M option exercise plus $140M dev/reg per target | $150M for each of 4 add'l targets | |||||||||||||
7 | Tag | Royalty reduced to co-excl or non-excl rate, as appropriate | 2/2020 | Queen’s University | Taysha Gene Therapies | 2013-20 IPOs | SEC Redacted | Deal | 3.20 | 23.20 | License | Preclinical | TSHA-101 (bicistronic tansgene AAV9 vector) for GM2 gangliosidosis | Exclusive | Worldwide | Central Nervous System, Endocrinological & Metabolic | Lysosomal Storage Disorders, Other Central Nervous System | Oligonucleotides | Gene Therapy | 10.00 | 13.20 | 10.00 | $10M, per Taysha's IPO prospectus | low single-digit royalties, per Taysha's IPO prospectus | ||||||||||||||||
8 | Tag | Royalty reduced to CL rate or to rate used to avoid a CL | 12/2019 | AbbVie | Aduro BioTech, Chinook Therapeutics | 2013-20 IPOs | SEC Redacted | Deal | 141.70 | 6.70 | Equity, License | Phase III | Atrasentan (endothelin receptor antagonist) for chronic kidney disease | Exclusive | Worldwide | Renal | Broad Focus Renal | Synthetics | Small Molecule | 6.70 | 141.70 | 6.8M Chinook shares with FMV of $6.7M, per Aduro's 7/20 S-4 | upper single-digit to high-teen royalties, per Aduro's 7/20 S-4 | $135M in agg milestones, per Aduro's 7/20 S-4 | |||||||||||||||||
9 | Tag | Royalty reduced to Generic Version rate, but not higher than CL rate | 12/2019 | Catalyst Biosciences | Biogen | Major Biotech | SEC Redacted | Deal | 15.00 | 355.00 | License, Research | Preclinical | CB 2782-PEG (anti-C3 protease) to treat dry age-related macular degeneration | Exclusive | Worldwide | Ophthalmic | Age-Related Macular Degeneration | Drug Delivery | PEG Products | 355.00 | mid-single to low double-digit royalties, per Catalyst's 2019 10-K | $340M in agg milestones, per Catalyst's 2019 10-K | ||||||||||||||||||
10 | Tag | Royalty reduced to Third Party Patent rate, max 50% reduction; CL rev not included in Net Sales | 12/2019 | Pulmatrix | Johnson & Johnson | Top Pharma | SEC Redacted | Deal | 7.20 | 103.60 | 2.00 | 2.00 | Co-Development, License, Option | Phase I, Formulation | RV1162/PUR1800 (kinase inhibitors) with inhaled iSPERSE delivery for COPD | Exclusive | Worldwide | Cancer, Respiratory | Chronic Obstructive Pulmonary Disease, Lung | Drug Delivery, Synthetics | Other, Small Molecule | 3.40 | 48.00 | 58.60 | 45.00 | $45M, per Pulmatrix' 2019 10-K | J&J pays $3.4M for tox study, per Pulmatrix' 2019 10-K; other dev cost pre-option are shared | 1-2% royalty, per Pulmatrix' 2019 10-K | $14M on option exercise, plus $34M in dev/reg milestones, per Pulmatrix' 2019 10-K | |||||||||||||
11 | Tag | CL revenue not included in Net Sales | 12/2019 | Theravance Biopharma | Pfizer | Top Pharma | SEC Redacted | Deal | 10.00 | 250.00 | License | Preclinical | Topically-applied skin-selective pan-JAK inhibitors for undisclosed skin conditions | Exclusive | Worldwide | Dermatologic | Drug Delivery, Synthetics | Small Molecule, Topical | 250.00 | mid-single to low double-digit royalties, per Theravance's 3Q20 | $240M in agg milestones, per Theravance's 3Q20 | |||||||||||||||||||
12 | Tag | Royalty reduced to CL rate | 10/2019 | Blueprint Medicines | Ipsen, Clementia Pharmaceuticals | Mid Tier Pharma, 2013-20 IPOs | SEC Redacted | Deal | 25.00 | 535.00 | License | Phase I, Orphan Indication | BLU-782 (ALK2 inhibitor) for fibrodysplasia ossificans progressiva | Exclusive | Worldwide | Other/Miscellaneous | Genetic Disorders | Synthetics | Small Molecule | 535.00 | low- to mid-teen royalty, per Blueprint's 9Q19 | $510M in agg milestones, per Blueprint's 9Q19 | ||||||||||||||||||
13 | Tag | Share equivalent to PS; CL rev not included in Net Sales | 10/2019 | Dicerna Pharmaceuticals | Roche | Top Pharma | SEC Redacted | Deal | 200.00 | 1,670.00 | Co-Development, Co-Promotion, License, Option, Research | Phase I, Discovery | RG6346 (DCR-HBVS) for hepatitis B | Exclusive | Worldwide | Infectious-Viral | Hepatitis B | Oligonucleotides | RNAi | 1,670.00 | up to mid-teen royalties; Dicerna has option to co-fund pivotal trials, for 20s-30s US royalties and US co-promotion rights, per Dicerna's 2019 10-K | $1.47B in agg milestones, per Dicerna's 2019 10-K | ||||||||||||||||||
14 | Tag | Royalty reduced to CON % of CL rate | 9/2019 | Chimerix | SymBio Pharmaceuticals | SEC Redacted | Deal | 5.00 | 185.00 | License | Preclinical | BCV (brincidofovir) for all indications except smallpox | Exclusive | Worldwide | Infectious-Viral | Broad Focus Infectious-Viral | 185.00 | low double-digit royalty, per Chimerix's 2019 10-K | $180M in agg milestones, per Chimerix's 2019 10-K | |||||||||||||||||||||
15 | Tag | Royalty reduced to CL rate or to rate used to avoid a CL | 9/2019 | KemPharm | Gurnet Point, Boston Pharmaceuticals | SEC Redacted | Deal | 10.00 | 493.00 | Co-Development, License, Option | Phase III, Preclinical | KP415 and KP484 SDX and d-MPH products for ADHD, option to KP879 and KP922 | Exclusive | Worldwide | Psychiatric | Attention Deficit Hyperactivity Disorder | Synthetics | Small Molecule | 63.00 | 73.00 | 420.00 | Royalties ranging from high single digits to mid-twenties in the US and low to mid-single digits in ex-US countries, per KemPharm's 9/4/19 8-K | $63M, per KemPharm's 9/4/19 8-K | Boston reimburses 3rd party costs only | |||||||||||||||||
16 | Tag | Royalty reduced to CL rate | 7/2019 | Jounce Therapeutics | Bristol-Myers Squibb, Celgene | Major Biotech, Top Pharma | SEC Redacted | Deal | 50.00 | 530.00 | License, Restatement | Preclinical | JTX-8064 anti-Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) antibody for cancer | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Monoclonals | 180.00 | 230.00 | 300.00 | mid single-digit to low double-digit royalties, per Jounce's 2019 10-K | |||||||||||||||||
17 | Tag | Royalty reduced to CL rate | 6/2019 | Arvinas | Bayer | Top Pharma | SEC Redacted | Deal | 17.50 | 749.50 | 32.50 | Equity, License, Research | Discovery | PROTAC protein degrader technology for cardiovascular, oncology and gynecologic diseases | Exclusive | Worldwide | Cancer, Cardiovascular, Genitourinary/Gynecologic | Broad Focus Cancer, Broad Focus Cardiovascular, Broad Focus Genitourinary/Gynecologic | Synthetics | Small Molecule | 32.50 | 12.00 | 197.50 | 259.50 | 490.00 | $490M, per Arvinas' 3Q20 | $12M R&D funding thru 2022, per Arvinas' 3Q20 | Mid-single to low double-digit royalties, per Arvinas' 3Q20 | $197.5M, per Arvinas' 3Q20 | $32.5M at 115% of FMV | |||||||||||||
18 | Tag | Royalty reduced to CON % of CL rate; CL not a sublicensee & CL rev not included in Net Sales | 12/2018 | Proteostasis Therapeutics | Roche, Genentech | Major Biotech, Top Pharma | SEC Redacted | Deal | 5.00 | 101.00 | License | Small molecule modulators for undisclosed target | Exclusive | Worldwide | Synthetics | Small Molecule | 101.00 | low single-digit royalties, per Proteostasis' 2018 10-K | $96M in agg milestones, per Proteostasis' 2018 10-K | |||||||||||||||||||||
19 | Tag | Royalty reduced to CL rate | 11/2018 | Zymeworks | BeiGene | 2013-20 IPOs | SEC Redacted | Deal | 20.00 | 722.00 | License, Research | Discovery | Azymetric and EFECT platforms for up to three bispecific antibodies for BeiGene selected targets | Exclusive | Worldwide | Unlimited | Monoclonals | Bispecific | 722.00 | $20M for Azymetric and EFECT agreement | $702M in development and commercial milestones for up to three bispecific product candidates under platform agreement. | |||||||||||||||||||
20 | Tag | Equitable royalty reduction to be negotiated after CL in such country | 10/2018 | Arrowhead Pharmaceuticals | Johnson & Johnson, Janssen | Top Pharma | SEC Redacted | Deal | 175.00 | 3,750.00 | 75.00 | Equity, License, Option, Research | Phase I, Discovery | ARO-HBV for hepatitis B and option for up to three additional RNAi therapeutics | Exclusive | Worldwide | Infectious-Viral | Hepatitis B | Oligonucleotides | RNAi | 75.00 | 3,750.00 | 3.26M common shares @ $23/sh | royalties to mid-teens under ARO-HBV license, and to low-teens under research collaboration, per Arrowhead's 12Q18 | $1.6B in agg milestones for ARO-HBV, plus $1.9M for three add'l targets, per Arrowhead's 12Q18 | ||||||||||||||||
21 | Tag | CL revenue not included in Net Sales | 10/2018 | Collplant | United Therapeutics, Lung Biotechnology | SEC Redacted | Deal | 5.00 | 44.00 | License, Option, Supply | Lead Molecule | hCollagen-based BioInk for 3D bioprinted lung transplants with option to 3 additional organs | Exclusive | Worldwide | Transplantation | Organ/Tissue Transplants | Collagen matrix, Recombinant DNA | 15.00 | 24.00 | 44.00 | Option exercise payments up to $9 million, $15M in additional development milestones for other manufactured organs | ||||||||||||||||||
22 | Tag | Royalty reduced to CON % of CL rate; CL not a sublicensee & CL rev not included in Net Sales | 10/2018 | SQZ Biotech | Roche | Top Pharma | SEC Redacted | Deal | 45.00 | 1,702.00 | 50.00 | Co-Development, Co-Promotion, License, Option, Research | Preclinical, Discovery | Mononuclear antigen presenting cells via HPV and tumor cell lycate (TCL) for oncology | Exclusive | Worldwide | Cancer, Infectious-Viral | Broad Focus Cancer, Other Infectious-Viral | Cell Therapy - Stem Cells/Factors, Transgenics | 457.00 | 502.00 | 1,200.00 | 50.00 | $45M | $1.2B, per SQZ's IPO prospectus | mid double-digit reimb of dev costs, per SQZ's IPO prospectus | mid-single digit to mid-teen royalties | $217M in dev plus $240M in reg milestones, per SQZ's IPO prospectus | 50% PS in US for TCL Products, per SQZ's IPO prospectus | |||||||||||||||
23 | Tag | Royalty reduced to CON %; same for Generic Sublicensee | 9/2018 | Precision BioSciences | Gilead | Major Biotech | SEC Redacted | Deal | 485.00 | License, Research, Termination | Discovery | ARCUS genome editing platform to develop HBV therapies | Exclusive | Worldwide | Infectious-Viral | Hepatitis B | Cell Therapy - Stem Cells/Factors | 40.00 | 105.00 | 145.00 | 340.00 | $340M, per Precision's IPO prospectus | $40M in research funding, per Precision's IPO prospectus | high single-digit to mid-teen royalties, per Precision's IPO prospectus | $105M, per Precision's IPO prospectus | |||||||||||||||||
24 | Tag | Royalty reduced by same % as Market Share Loss w CON % floor & carryforward; same for comp product | 8/2018 | Ionis Pharmaceuticals, Akcea Therapeutics | PTC Therapeutics | 2013-20 IPOs | SEC Redacted | Deal | 12.00 | 26.00 | License, Supply | Filed, Orphan Indication | Tegsedi (inotersen) and Waylivra (volanesorsen) for orphan neuro and metabolic diseases in SA | Exclusive | NAFTA, South America | Central Nervous System, Endocrinological & Metabolic | Other Central Nervous System, Other Endocrinological & Metabolic | Oligonucleotides | Antisense/Triple helix | 4.00 | 10.00 | 26.00 | $12M upfront for Tegsedi, per PTC's 9Q18 | mid-twenties royalties, per Akcea's 9Q18 | $4M on Brazil approval of Tegsedi, per PTC's 9Q18 | $6M on Waylivra FDA or EMA approval, plus $4M on Brazil approval, per PTC's 9Q18 | ||||||||||||||||
25 | Tag | Royalty reduced to CL rate | 7/2018 | Sutro Biopharma | Merck | Top Pharma | SEC Redacted | Deal | 60.00 | 1,690.00 | 30.00 | Equity, License, Option, Research, Supply | Discovery | Cell-free protein synthesis & site-specific conjugation platform for cancer & autoimmune diseases | Exclusive | Worldwide | Autoimmune/Inflammatory, Cancer | Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer | Monoclonals | Conjugates | 20.00 | 10.00 | 1,690.00 | $10M at IPO, per Sutro's IPO prospectus | Mid-single digit to low teen royalties, per Sutro's IPO prospectus | $1.6B in agg milestones, per Sutro's IPO prospectus | |||||||||||||||
26 | Tag | CL revenue not included in Net Sales; minimum royalties to be renegotiated if CL or generic competition | 5/2018 | LipimetiX | Anji Pharmaceuticals | SEC Full | Deal | Sublicense | Apo E mimetic peptide platform including AEM-28 and analogs in China | Exclusive | Asia | Peptides | |||||||||||||||||||||||||||
27 | Tag | Royalty reduced to CL rate | 4/2018 | Children's Hospital of Philadelphia, University of Pennsylvania | Cabaletta Bio | 2013-20 IPOs | SEC Redacted | Deal | 29.70 | 1.20 | Equity, License, Research | Preclinical, Orphan Indication | DSG3-CAART therapy for B cell-mediated autoimmune diseases | Exclusive | Worldwide | Autoimmune/Inflammatory | Other Autoimmune/Inflammatory | Cell Therapy - Stem Cells/Factors | 1.20 | 8.50 | 29.70 | $8.5M over 3 yrs | low single digit royalty, per Cabaletta's IPO prospectus | $20M in agg milestones, per Cabaletta's IPO prospectus | 481K common shares, with FMV of $1.2M, per Cabaletta's IPO prospectus | |||||||||||||||||
28 | Tag | If CL rate is below 3rd Party Patent or Biosimilar rate, then 50% sharing | 2/2017 | Adimab | X4 Pharmaceuticals, Arsanis | 2013-20 IPOs | FOIA | Deal | 24.76 | 4.00 | 4.00 | License, Option, Research | Lead Molecule | RSV antibody program | Exclusive | Worldwide | Infectious-Viral | Respiratory Syncytial Virus/RSV | Monoclonals | Human Abs | 0.33 | 16.50 | 8.13 | 24.63 | 4.00 | 4.00 | 4.00 | ||||||||||||
29 | Tag | CL royalty reduced to "such rate as would be reasonable" | 4/2016 | Lantheus Medical Imaging, Progenics Pharmaceuticals | Bayer | Top Pharma | FOIA | Deal | 4.00 | 183.00 | 5.00 | License | Lead Molecule | PSMA antibody Conjugated with targeted thorium for prostate cancer | Exclusive | Worldwide | Cancer | Prostate | Monoclonals | Conjugates, Human Abs | 49.00 | 53.00 | 130.00 | 3.00 | 3.00 | 4.00 | |||||||||||||
30 | Tag | Royalty reduced to CL rate, with add'l adjustments for 3rd Party Patents | 1/2016 | Macrolide | Melinta Therapeutics, Cempra | 2003-12 IPOs | FOIA | Deal | 0.75 | 5.25 | 1.00 | 1.00 | License, Option, Research, Termination | Lead Molecule | Methods of synthesizing solithromycin ex-Asean | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Infectious-Bacterial | Broad Focus Infectious-Bacterial | 1.50 | 2.00 | 4.25 | 1.00 | 1.00 | 1.00 | 1.00 | $1.5M over 18 months | ||||||||||||
31 | Tag | Royalty reduced to CL rate | 2/2015 | University of Pennsylvania | Allergan, AbbVie, Kythera Biopharmaceuticals | Top Pharma, Mid Tier Pharma, 2003-12 IPOs | FOIA | Deal | 0.22 | 4.34 | 4.00 | 4.00 | License | Preclinical | IP covering use of PGD2 receptor antagonists for hair loss | Exclusive | Worldwide | Other/Miscellaneous | Hair Growth | Synthetics | Small Molecule | 0.88 | 0.25 | 1.34 | 3.00 | 2.00 | 2.00 | 3.00 | |||||||||||
32 | Tag | Royalty reduced to 50% of CL rate, plus 50% of any add'l CL payments; max royalty reduction of 75% | 2/2014 | Ardelyx | Sanofi | Top Pharma | FOIA | Deal | 1.25 | 198.00 | 11.00 | 11.00 | Co-Promotion, Development, License, Option, Termination | Preclinical | NaP2b phosphate transport inhibitor for kidney disease | Exclusive | Worldwide | Renal | Kidney Stones, Other Renal | Synthetics | Small Molecule | 0.25 | 196.75 | 198.00 | 6.00 | 7.00 | 9.00 | $10M on option exercise, plus $186.75M in dev/reg milestones | |||||||||||
33 | Tag | Royalty reduced to CL rate | 12/2013 | BioVascular | Galena Biopharma, Sellas Life Sciences Group, Mills Pharmaceuticals | FOIA | Deal | 0.10 | 13.90 | 6.00 | 6.00 | License | Phase I, Formulation | CR formulation of anagrelide for cancer & cardio | Exclusive | Worldwide | Cancer, Cardiovascular | Leukemia, Myocardial Infarction | Drug Delivery | Controlled Release | 6.85 | 6.95 | 13.90 | 5.00 | 6.00 | 6.00 | $6.95M for Cardio Field | ||||||||||||
34 | Tag | CRE to oppose CL; royalty reduced to CL rate or to rate used to avoid a CL | 2/2013 | Acer Therapeutics, Opexa Therapeutics | Merck KGaA, Merck Serono | Top Pharma | FOIA | Deal | 5.00 | 225.00 | 18.00 | 18.00 | Co-Development, License, Option, Supply | Phase II, Orphan Indication | Tcelna (imilecleucel-T) autologous T-cell therapy for multiple sclerosis ex-Japan | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Central Nervous System | Multiple Sclerosis | Cell Therapy - Stem Cells/Factors, Vaccines | 0.30 | 95.00 | 40.00 | 140.00 | 85.00 | 8.00 | 8.00 | 9.00 | $5M option fee | 8-15% royalty, increased to 10-18% if Opexa pays 33% of 1st indication | $25M option exercise, plus $70M dev/reg 1st | $40M for relapsing remitting MS indication | ||||||||||
35 | Tag | CRE to oppose CL; royalty reduced to CL rate plus 50% of any add'l CL payments; max royalty reduction of 50% w carryforward | 10/2012 | Ardelyx | AstraZeneca | Top Pharma | FOIA | Deal | 35.00 | 860.00 | 20.00 | 20.00 | Co-Development, Co-Promotion, Development, License, Option, Termination | Phase II | Tenapanor (RDX5791 NHE3 inhibitor) for IBS-C, end stage renal & kidney disease | Exclusive | Worldwide | Gastrointestinal, Renal | IBD - Other, Nephritis - Other, Other Renal | Synthetics | Small Molecule | 0.25 | 215.00 | 250.00 | 500.00 | 360.00 | 9.00 | 9.00 | 11.00 | 9-17% royalty, plus 1-3% add'l if Ardelyx funds $20-40M of Ph III trials | $215M for constipation-related indication | |||||||||
36 | Tag | CRE to oppose CL; royalty reduced to CL rate | 7/2012 | Georgia Tech, Emory University | Clearside Biomedical | 2013-20 IPOs | FOIA | Deal | 0.14 | 0.25 | 3.00 | 3.00 | License | Device | Microneedle for ocular procedure and tissue injections | Exclusive | Worldwide | Ophthalmic | Broad Focus Ophthalmic | Drug Delivery | Other | 0.11 | 0.25 | 3.00 | 3.00 | 3.00 | |||||||||||||
37 | Tag | Royalty reduced to CL rate | 4/2012 | Novartis, Endocyte | Merck | Top Pharma | FOIA | Deal | 120.00 | 1,001.50 | 50.00 | 20.00 | Co-Development, Co-Promotion, License, Option, Termination | Phase III | Vintafolide (EC145) folate conjugate for lung & ovarian cancer | Exclusive | Worldwide | Cancer | Lung, Ovarian | Synthetics | Small Molecule | 0.25 | 47.50 | 334.00 | 501.50 | 500.00 | 14.00 | 14.00 | 15.00 | 50.00 | Endocyte pays 75% of PROC (ovarian) Ph III plus 100% of Companion Diagnostic; Merck pays all other dev costs | 14-20% ex-US royalty | $47.5M for Ovarian (PROC) | $60M for Lung; $274N for Other Indications | 50% PS in US | ||||||||
38 | Tag | Royalty reduced to CL rate | 9/2011 | Children’s Cancer Institute Australia | Cleveland BioLabs, Panacela Labs | 2003-12 IPOs | FOIA | Deal | 6.50 | 2.00 | 2.00 | Equity, License, Option | Preclinical | Small Molecules Inhibiting Oncoprotein MYC for solid tumor treatment | Exclusive | Worldwide | Cancer | Solid Tumors | Synthetics | Small Molecule | 6.50 | 6.50 | 2.00 | 2.00 | 2.00 | 2% of OS shares at signing | |||||||||||||
39 | Tag | Royalty reduced to CL rate | 9/2011 | Roswell Park Cancer Institute, Health Research Inc | Cleveland BioLabs, Panacela Labs | 2003-12 IPOs | FOIA | Deal | 0.02 | 3.20 | 1.00 | 1.00 | Equity, License, Option, Research | Preclinical, Lead Molecule | Curaxin CBL0137, TLR-5 agonist & MYC inhibitor for treatment of cancer | Exclusive | Worldwide | Cancer | Broad Focus Cancer | 0.85 | 2.33 | 3.20 | 1.00 | 1.00 | 1.00 | $24.8K for patent costs | 1656 common shares | 1% royalty (3% if sold before FDA approval) | |||||||||||||
40 | Tag | Royalty reduced to CL rate | 5/2011 | Adimab | X4 Pharmaceuticals, Arsanis | 2013-20 IPOs | FOIA | Deal | 0.05 | 1.20 | 6.00 | 6.00 | License, Option, Research | Discovery | Yeast monoclonals against bacterial lipopolysaccharide (LPS) targets | Exclusive | Worldwide | Infectious-Bacterial | Broad Focus Infectious-Bacterial | Monoclonals | Human Abs | 1.10 | 0.28 | 1.20 | 6.00 | 6.00 | 6.00 | Min 4 FTEs @ $280K/FTE for 1 yr | |||||||||||
41 | Tag | 50% of Net Sales disregarded in country w CL; max royalty reduction of 50% w carryforward | 12/2009 | Catalyst Biosciences, Targacept | AstraZeneca | Top Pharma | FOIA | Deal | 200.00 | 1,240.00 | 25.00 | 25.00 | Co-Development, Co-Promotion, License, Option, Research, Termination | Phase II | Amplixa (TC-5214 nicotinic channel blocker) for major depressive disorder | Exclusive | Worldwide | Psychiatric | Depression & Mania | Synthetics | Small Molecule | 0.25 | 285.00 | 255.00 | 740.00 | 500.00 | 20.00 | 21.00 | 23.00 | 20% in US; 16% in ROW | 21% in US; 17% in ROW | 22.5% in US; 18.5% in ROW | 25% max US royalty; 22% in ROW | $285M for adjunct therapy | $255M for monotherapy | |||||||||
42 | Tag | Royalty reduced to CL rate w add'l adjustment for Generic Competition | 12/2009 | Daiichi Sankyo, Ambit Biosciences | Astellas Pharma | Top Pharma, Japanese Pharma | FOIA | Deal | 40.00 | 355.00 | 50.00 | 22.00 | Co-Development, Co-Promotion, License, Research, Termination | Phase II | AC220 (quizartinib FLT3 kinase inhibitor) for acute myeloid leukemia | Exclusive | Worldwide | Cancer | Leukemia | Synthetics | Small Molecule | 0.29 | 140.00 | 170.00 | 350.00 | 5.00 | 12.00 | 15.00 | 19.00 | 50.00 | 12-22% ex-US royalty | $140M for AML | $100M for add'l oncology, plus $70M for non-oncology indications | 50/50 PS in US if co-promote | ||||||||
43 | Tag | Royalty reduced to CL rate, but with 1% royalty floor | 12/2009 | Ionis Pharmaceuticals | Lilly | Top Pharma | FOIA | Deal | 105.00 | 10.00 | 10.00 | Co-Development, License, Option | Phase I | Eukaryotic initiation factor 4E (LLY2275796 eIF-4E antisense compound) for cancer | Exclusive | Worldwide | Cancer | Colorectal | Oligonucleotides | Antisense/Triple helix | 55.00 | 50.00 | 105.00 | 5.00 | 5.00 | 7.00 | $30-50M on license option exercise | ||||||||||||
44 | Tag | Royalty reduced to CL rate w add'l adjustment for Generic Competition | 12/2008 | Actavis, Allergan, AbbVie, MAP Pharmaceuticals | AstraZeneca | Top Pharma | FOIA | Deal | 40.00 | 900.00 | 30.00 | 30.00 | Co-Promotion, Development, License | Phase III, Formulation | Unit Dose Budesonide for pediatric asthma | Exclusive | Worldwide | Respiratory | Asthma | Drug Delivery | Nasal | 0.35 | 290.00 | 55.00 | 385.00 | 515.00 | 19.00 | 19.00 | 19.00 | 30% US max rate; 20% ROW max rate | |||||||||
45 | Tag | Royalty reduced to CL rate | 12/2008 | Ligand | GlaxoSmithKline | Top Pharma | FOIA | Deal | 5.00 | 163.00 | 16.00 | 16.00 | License | Phase II, Orphan Indication | LGD-4665 thrombopoietin mimetic for treatment of thrombocytopenia | Exclusive | Worldwide | Hematologic | Thrombocytopenia | Synthetics | Small Molecule | 83.00 | 88.00 | 75.00 | 16.00 | 16.00 | 16.00 | 8% for first yr, then 16% thereafter | |||||||||||
46 | Tag | Net Sales in country w CL calculated on basis of CL royalty only | 10/2008 | Lpath | Merck KGaA, Merck Serono | Top Pharma | FOIA | Deal | 4.00 | 467.50 | 15.00 | 15.00 | Development, License | Phase I | Sonepcizumab ( sphingosine-I-phosphate antibody) for solid tumors & MS | Exclusive | Worldwide | Cancer, Central Nervous System | Multiple Sclerosis, Solid Tumors | Monoclonals | Humanized Abs | 6.00 | 92.50 | 322.00 | 424.50 | 43.00 | 7.00 | 7.00 | 9.00 | $500K/month for 1 yr | |||||||||
47 | Tag | Royalty reduced to 50% of CL rate, plus 50% of any add'l CL payments | 12/2007 | Idera Pharmaceuticals | Merck Serono, Merck KGaA | Top Pharma | FOIA | Deal | 40.00 | 431.40 | 13.00 | 13.00 | Development, License, Termination | Phase II, Preclinical | IMO-2055 and IMO-2125 (TLR9 agonists) for the treatment of cancer excluding vaccines | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Oligonucleotides | Antisense/Triple helix | 0.70 | 57.70 | 288.60 | 387.00 | 44.40 | 5.00 | 5.00 | 6.00 | $700K reimb for current trials | |||||||||
48 | Tag | Royalty reduced to CL rate | 12/2007 | University of British Columbia | QLT | FOIA | Deal | 0.05 | 0.05 | 2.00 | 2.00 | License, Restatement | Approved | Visudyne (beverteportin) photodynamic therapy | Exclusive | Worldwide | Ophthalmic | Age-Related Macular Degeneration | Phototherapy | 0.05 | 2.00 | 2.00 | 2.00 | Cdn$5K AMF plus $30K legal costs | |||||||||||||||
49 | Tag | Royalty reduced to CL rate | 11/2007 | Oncternal Therapeutics, GTx | Merck | Top Pharma | FOIA | Deal | 40.00 | 592.00 | 23.00 | 30.00 | 23.00 | Co-Development, Co-Promotion, Equity, License, Research, Termination | Phase II, Preclinical, Lead Molecule | Ostarine (selective androgen receptor modulator) for cancer-related muscle loss | Exclusive | Worldwide | Cancer, Endocrinological & Metabolic | Other Cancer, Other Endocrinological & Metabolic | Synthetics | Small Molecule | 30.00 | 15.00 | 60.00 | 447.00 | 592.00 | 13.00 | 13.00 | 13.00 | 1.285M common shares @ $23.34/sh (see Equity agmt) | $5M in R&D funding/yr for 3 yrs | $60M for Ostarine for Cancer Cachexia | $220M for sarcopenia; $142M add'l for cancer cachexia; $85M for any other indication | ||||||||
50 | Tag | Royalty reduced to CL rate w add'l adjustment for 3rd Party Patents | 10/2007 | Bayer | Midatech, Dara Biosciences | 1991-2001 IPOs | FOIA | Deal | 0.60 | 16.35 | 14.00 | 14.00 | License | Preclinical | PPAR compounds (including Bay62-9069) for Type 2 diabetes & dyslipidemia | Exclusive | Worldwide | Endocrinological & Metabolic | Diabetes | Synthetics | Small Molecule | 10.50 | 5.25 | 16.35 | 11.00 | 12.00 | 12.00 | $10.5M for Type 2 diabetes | |||||||||||
51 | Tag | Royalty reduced to CL rate | 9/2007 | Akebia Therapeutics, Keryx Biopharmaceuticals | Japan Tobacco, Torii Pharmaceutical | Japanese Pharma | FOIA | Deal | 20.00 | 100.00 | 14.00 | 14.00 | License | Phase II | Auryxia/Riona (ferric citrate) for hyperphosphatemia in Japan | Exclusive | Asia | Endocrinological & Metabolic, Renal | Other Endocrinological & Metabolic, Other Renal | Synthetics | Small Molecule | 25.00 | 45.00 | 55.00 | 11.00 | 13.00 | 14.00 | ||||||||||||
52 | Tag | Royalty reduced to CL rate | 9/2007 | Dainippon Sumitomo, Sunovion Pharmaceuticals | GlaxoSmithKline | Top Pharma | FOIA | Deal | 20.00 | 155.00 | 23.00 | 23.00 | Distribution, License, Termination | Filed | Lunivia (eszopiclone) for treatment of insomnia ex-NAFTA and Japan | Exclusive | Africa, Asia, Europe, Middle East, South America | Central Nervous System | Sleep Disorders | Drug Delivery | Oral | 45.00 | 65.00 | 90.00 | 14.00 | 19.00 | 21.00 | 25.00 | |||||||||||
53 | Tag | If CL granted, parties will consult and cooperate to be competitive | 8/2007 | Aradigm | United Therapeutics, Lung Biotechnology | FOIA | Deal | 0.88 | 14.00 | 10.00 | 3.47 | 10.00 | Co-Development, Equity, License | Phase II, Formulation | Tyvaso (AERx pulmonary delivery of treprostinil) for arterial hypertension | Exclusive | Worldwide | Cardiovascular | Hypertension | Drug Delivery | Nasal | 3.47 | 9.65 | 14.00 | 9.00 | 7.00 | 5.00 | ||||||||||||
54 | Tag | Royalty reduced to CL rate | 6/2007 | SurModics | Merck | Top Pharma | FOIA | Deal | 20.00 | 207.50 | 9.00 | 9.00 | Development, License, Supply, Termination | Phase I, Lead Molecule, Formulation | I-vation SR delivery of triamcinolone acetonide and KDR kinase inhibitors for macular edema & AMD | Exclusive | Worldwide | Ophthalmic | Broad Focus Ophthalmic, Age-Related Macular Degeneration | Drug Delivery | Sustained Release | 3.50 | 78.00 | 106.00 | 207.50 | 9.00 | 9.00 | 9.00 | 65.00 | 9% for TA Product; 4-8% for KDR Product or Other Target(s) | SurModic's Profit of 65% over Economic Cost (see Supply agmt) | |||||||||
55 | Tag | Net Sales in country w CL calculated on basis of CL royalty only | 5/2007 | Transcept Pharmaceuticals, Paratek Pharmaceuticals, Novacea | Merck, Schering-Plough | Top Pharma | FOIA | Deal | 60.00 | 452.00 | 24.00 | 12.00 | 24.00 | Co-Promotion, Development, Equity, License, Termination | Phase III | Asentar (DN-101 oral calcitriol) for prostate cancer | Exclusive | Worldwide | Cancer | Prostate | Synthetics | Small Molecule | 12.00 | 0.25 | 50.00 | 330.00 | 452.00 | 18.00 | 19.00 | 21.00 | |||||||||
56 | Tag | Royalty reduced to CL rate | 5/2007 | University of Maastricht | BG Medicine Inc. | 2003-12 IPOs | FOIA | Deal | 0.75 | 2.00 | 2.00 | Development, License | Diagnostic | Biomarker-based molecular diagnostic test as a prognostic indicator of congestive heart failure | Exclusive | Worldwide | Cardiovascular | Congestive Heart Failure | Diagnostics | 0.75 | 0.75 | 2.00 | 2.00 | 2.00 | |||||||||||||||
57 | Tag | Royalty reduced to CL rate | 4/2007 | Pfizer, Coley Pharmaceutical | Merck | Top Pharma | FOIA | Deal | 4.00 | 15.50 | 4.00 | 4.00 | License | Lead Molecule | VaxImmune adjuvant for use in vaccines | Non-exclusive | Worldwide | Infectious-Viral | Broad Focus Infectious-Viral | Adjuvant, Vaccines | 11.00 | 0.50 | 15.50 | 4.00 | 4.00 | 4.00 | |||||||||||||
58 | Tag | Royalty reduced to CL rate | 3/2007 | Clinical Data, Avalon Pharmaceuticals | Merck | Top Pharma | FOIA | Deal | 202.00 | 10.00 | 10.00 | Co-Development, License, Research | Discovery | AvalonRx platform to screen compounds for STAT3 inhibitors to treat cancer | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Screening | 108.00 | 64.00 | 172.00 | 30.00 | 8.00 | 8.00 | 9.00 | |||||||||||||
59 | Tag | Royalty reduced to CL rate w add'l adjustment for 3rd Party Patents | 3/2007 | SLA Pharma | Assembly BioSciences | FOIA | Deal | 0.25 | 26.50 | 8.00 | 8.00 | Development, Equity, License | Phase II, Formulation | Anoheal (topical diltiazem) & Incostop (topical phenylephrine) for pain from anal fissures | Exclusive | NAFTA | Genitourinary/Gynecologic | Other Genitourinary/Gynecologic | Drug Delivery | Topical | 6.00 | 7.13 | 13.13 | 26.50 | 7.00 | 8.00 | 8.00 | 5% of OS shares of Licensee | $83K/month for 2 yrs plus $4M for EU clinical costs | $7.125M for Anoheal | $13.125 for Incostop | |||||||||||
60 | Tag | Royalty reduced to CL rate | 2/2007 | GW Pharmaceuticals | Otsuka Pharmaceutical | Top Pharma, Japanese Pharma | FOIA | Deal | 18.00 | 303.70 | 25.00 | 5.00 | Development, License, Supply, Termination | Phase III, Orphan Indication | Sativex (cannabis-based medicinal extract) for MS, neuopathic and cancer pain in US | Exclusive | NAFTA | Cancer, Central Nervous System | Broad Focus Cancer, Multiple Sclerosis, Pain | Natural Product | 30.70 | 25.00 | 30.00 | 103.70 | 200.00 | 20.00 | $30.7M for 1st indication | 5% royalty (plus transfer price) | ||||||||||||
61 | Tag | Royalty reduced to CL rate | 12/2006 | Idera Pharmaceuticals | Merck | Top Pharma | FOIA | Deal | 20.00 | 455.00 | 10.00 | 8.00 | Equity, License, Research | Discovery | Toll-like Receptor (TLR) agonists for cancer, infection & Alzheimers vaccines | Exclusive | Worldwide | Cancer, Central Nervous System, Infectious-Viral | Broad Focus Cancer, Broad Focus Infectious-Viral, Alzheimer's Disease | Oligonucleotides, Vaccines | Ligands | 10.00 | 5.00 | 60.00 | 185.00 | 280.00 | 5.00 | 5.00 | 6.00 | $60M for Alzheimer's | |||||||||
62 | Tag | Royalty reduced to CL rate | 12/2006 | Nuada | Midatech, Dara Biosciences | 1991-2001 IPOs | FOIA | Deal | 0.01 | 6.00 | 3.00 | 3.00 | License | Lead Molecule | Peptidase inhibitors | Exclusive | Worldwide | Unlimited | Peptides | 5.95 | 6.00 | 3.00 | 3.00 | 3.00 | |||||||||||||||
63 | Tag | Royalty reduced to CL rate | 10/2006 | InterMune | Roche | Top Pharma | FOIA | Deal | 60.00 | 560.00 | 19.00 | 19.00 | Co-Development, Co-Promotion, License, Termination | Preclinical | Danoprevir (ITMN-191) cyclic macrocycle for HCV | Exclusive | Worldwide | Infectious-Viral | Hepatitis C | Peptides | 250.00 | 310.00 | 240.00 | 14.00 | 15.00 | 17.00 | 50.00 | ||||||||||||
64 | Tag | CRE to oppose CL; royalty reduced to CL rate, except no royalty on Product provided at or below cost in crisis | 10/2006 | Ligand, Metabasis Therapeutics | Merck, Idenix Pharmaceuticals | Top Pharma, 2003-12 IPOs | FOIA | Deal | 2.00 | 68.80 | 9.00 | 9.00 | Development, License, Research | Discovery | HepDirect liver-targeting technology for HCV | Exclusive | Worldwide | Infectious-Viral | Hepatitis C | Drug Delivery, Screening, Synthetics | Other, Small Molecule | 3.30 | 0.28 | 63.50 | 68.80 | 6.00 | 7.00 | 8.00 | |||||||||||
65 | Tag | Royalty reduced to CL rate | 10/2006 | Meiji Seika | MediciNova | 2003-12 IPOs | FOIA | Deal | 0.40 | 9.05 | 9.00 | 9.00 | License | Lead Molecule | CP4715 (alphaVbeta3 / GPIIb/IIIa receptor dual antag) for cardio ex-Japan, China, Korea & ASEAN | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Cardiovascular | Broad Focus Cardiovascular | Synthetics | Small Molecule | 8.65 | 9.05 | 5.00 | 7.00 | 8.00 | 5-7% in US & 5-7% in ROW | ||||||||||||
66 | Tag | Royalty reduced to CL rate | 10/2006 | Meiji Seika | MediciNova | 2003-12 IPOs | FOIA | Deal | 0.40 | 9.05 | 9.00 | 9.00 | License | Lead Molecule | EF6265 (fibrinolysis inhibitor) & EF6243 antithrombotic for cardio ex-Japan, China, Korea & ASEAN | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Cardiovascular | Broad Focus Cardiovascular | Synthetics | Small Molecule | 8.65 | 9.05 | 5.00 | 7.00 | 8.00 | 5-9% in US & 5-7% in ROW | ||||||||||||
67 | Tag | Royalty reduced to CL rate | 8/2006 | Adare Pharmaceuticals, Eurand | Otsuka Pharmaceutical, Avanir Pharmaceuticals | Top Pharma, Japanese Pharma | FOIA | Deal | 0.10 | 23.20 | 5.00 | 5.00 | Development, License | Preclinical, Formulation | Diffucaps CR formulation of ZENVIA for pain | Exclusive | Worldwide | Central Nervous System | Pain | Drug Delivery | Controlled Release | 1.58 | 5.00 | 6.68 | 14.00 | 5.00 | 5.00 | 5.00 | |||||||||||
68 | Tag | Royalty reduced to CL rate | 7/2006 | Alnylam | Merck | Top Pharma | FOIA | Deal | 84.50 | 50.00 | 15.00 | Co-Development, Co-Promotion, License, Option, Research, Restatement, Termination | Discovery | RNAi for nine non-druggable targets | Exclusive | Worldwide | Unlimited | Oligonucleotides | RNAi | 0.49 | 41.00 | 43.50 | 84.50 | 10.00 | 12.00 | 13.00 | 50.00 | 10-15% ROW royalty for RNAi Products; 5-10% on Merck Development Products | $30.5M for Opt-out RNAi Product; $5.5M for Profit Sharing RNAi Product; $7.5M on Merck's Opt-in for RHOA Product | 50/50 PS on Profit Sharing RNAi Products in US | $41M for Merck Development Products | |||||||||||
69 | Tag | CRE to oppose CL; if CL only distributes, country Net Sales based on all CL payments; if CL supplies, royalty is 20% of all CL payments | 6/2006 | Adhera Therapeutics | Bristol-Myers Squibb, Amylin | Top Pharma, 1991-2001 IPOs | FOIA | Deal | 89.00 | 9.00 | 9.00 | Development, License, Supply | Preclinical, Formulation | Intranasal delivery of Exenatide for treatment of diabetes | Exclusive | Worldwide | Endocrinological & Metabolic | Diabetes | Drug Delivery | Nasal | 0.35 | 24.00 | 24.00 | 65.00 | 7.00 | 9.00 | 9.00 | 15.00 | |||||||||||
70 | Tag | Royalty reduced to CL rate | 6/2006 | Cedars-Sinai Medical Center | Salix Pharmaceuticals | FOIA | Deal | 1.30 | 1.30 | 2.00 | 2.00 | Development, License | Rifaximin for treatment of IBS | Exclusive | Worldwide | Gastrointestinal | Bowel Movement Disorders, IBD - Other | Drug Delivery | Oral | 1.30 | 2.00 | 2.00 | 2.00 | ||||||||||||||||
71 | Tag | Royalty reduced to CL rate | 5/2006 | Dainippon Sumitomo | Lundbeck A/S, Chelsea Therapeutics | Mid Tier Pharma | FOIA | Deal | 0.10 | 4.35 | 5.00 | 0.25 | 5.00 | Equity, License, Supply | Approved, Orphan Indication | L-Threo DOPS (Droxidopa) for neurogenic orthostatic hypotension ex-Japan, Korea and China | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Central Nervous System | Other Central Nervous System | Synthetics | Small Molecule | 0.25 | 3.00 | 3.35 | 1.00 | 5.00 | 5.00 | 5.00 | 10.00 | |||||||||
72 | Tag | Royalty reduced to CL rate | 3/2006 | Gilead, Myogen | GlaxoSmithKline | Top Pharma | FOIA | Deal | 20.00 | 100.00 | 35.00 | 35.00 | Co-Development, License | Phase III | Volibris (ambrisentan) for PAH ex-US | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Cardiovascular | Hypertension | Synthetics | Small Molecule | 45.00 | 8.00 | 73.00 | 27.00 | 27.00 | 32.00 | 34.00 | |||||||||||
73 | Tag | CRE to oppose CL; negotiate approprate royalty adjustments | 1/2006 | Adhera Therapeutics | Procter & Gamble | Mid Tier Pharma | FOIA | Deal | 10.00 | 577.00 | 23.00 | 23.00 | Co-Promotion, Development, License, Supply, Termination | Phase II, Formulation | PTH1-34 (parathyroid hormone nasal spray) for treatment of osteoporosis | Exclusive | Worldwide | Bone Disease | Osteoporosis | Drug Delivery | Nasal | 0.28 | 48.00 | 74.00 | 132.00 | 445.00 | 10.00 | 13.00 | 18.00 | Cost of materials plus $0.75/Unit (see 6/06 Supply Agmt) | |||||||||
74 | Tag | Royalty in such country (or all Europe if in Europe) reduced to CL rate & thresholds for rates & sales milestones shall be adjusted down | 12/2005 | Catalyst Biosciences, Targacept | AstraZeneca | Top Pharma | FOIA | Deal | 10.00 | 373.40 | 19.00 | 19.00 | Co-Promotion, Development, License, Option, Research, Termination | Phase II, Discovery | Neuronal nicotinic receptors, including TC-1734 for Alzheimer's and cognitive dysfunction | Exclusive | Worldwide | Central Nervous System, Psychiatric | Alzheimer's Disease, Schizophrenia | Synthetics | Small Molecule | 26.40 | 0.27 | 165.00 | 172.00 | 373.40 | 11.00 | 11.00 | 12.00 | $26.4M over 4 yrs | IND: $10M on Option Compound exercise, plus $75M dev/reg; POC: $42M on exercies, plus $130M dev/reg | |||||||||
75 | Tag | Royalty reduced to CL rate | 12/2005 | Lilly | Targanta Therapeutics, The Medicines Company, InterMune, Novartis, Melinta Therapeutics | Top Pharma, 2003-12 IPOs, 1991-2001 IPOs | FOIA | Deal | 3.00 | 70.00 | 18.00 | 18.00 | Asset Purchase, License, Restatement | Approved | Orbactiv (oritavancin) for bacterial skin infections | Exclusive | Worldwide | Infectious-Bacterial | Other Infectious-Bacterial | Peptides | 13.00 | 10.00 | 29.00 | 55.00 | 15.00 | 10.00 | 13.00 | 16.00 | $2M to InterMune plus $1M to Lilly (per 12/05 Asset Agmt) | $15M to Lilly | 10-18% royalty to Lilly | $13M convertible note from Targanta to InterMune (per 12/05 Asset Agmt) | $10M to Lilly for 1st indication | $10M to LIlly for 2nd indication; $19M to InterMune (per 12/05 Asset Agmt) | ||||||||||
76 | Tag | 50% of all payments made by CL licensee & CL Net Sales not included in minimum annual royalty calc | 12/2005 | Maxygen | Roche | Top Pharma | FOIA | Deal | 8.00 | 104.00 | 37.00 | 37.00 | Co-Development, License, Option, Termination | Preclinical | MAXY_VII (recombinant factor VIIa) for acute bleeding indications | Exclusive | Worldwide | Hematologic | Other Hematologic | Recombinant DNA | 0.35 | 52.00 | 44.00 | 104.00 | 28.00 | 30.00 | 34.00 | 27-37% in US; 20-30% in ROW | |||||||||||
77 | Tag | Royalty reduced to CL rate | 11/2005 | Panion & BF | Akebia Therapeutics, Keryx Biopharmaceuticals | 2013-20 IPOs, 1991-2001 IPOs | FOIA | Deal | 0.10 | 8.95 | 6.00 | 6.00 | Co-Development, License | Phase II | Zerenex (ferric citrate) for hyperphosphatemia in end stage renal disease ex-Asian Pacific | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Renal | Other Renal | Synthetics | Small Molecule | 0.35 | 8.50 | 8.95 | 6.00 | 6.00 | 6.00 | $350K to reimb 50% of current Ph II | |||||||||||
78 | Tag | Royalty reduced to CL rate | 9/2005 | Eiffel Technologies | Allergan, AbbVie, MAP Pharmaceuticals | Top Pharma, Mid Tier Pharma, 2003-12 IPOs | FOIA | Deal | 11.60 | 4.00 | 4.00 | Assignment, Development, License, Supply | Formulation | Inhalation delivery of insulin & beta-agonist with steroid | Exclusive | Worldwide | Endocrinological & Metabolic, Respiratory | Asthma, Chronic Obstructive Pulmonary Disease, Diabetes | Drug Delivery | Nasal, Other | 0.60 | 5.75 | 5.25 | 11.60 | 4.00 | 4.00 | 4.00 | ||||||||||||
79 | Tag | Royalty reduced to CL rate | 9/2005 | ev3, Covidien, Foxhollow Technologies | Merck | Top Pharma | FOIA | Deal | 6.00 | 52.00 | 3.00 | 3.00 | License, Research | Phase I | Predictive markers for development of cardiovascular compounds & tests | Exclusive | Worldwide | Cardiovascular | Atherosclerosis/Coronary Artery Disease, Hypertension, Peripheral Arterial Disease | Genomics | Pharmacogenomics | 5.00 | 34.00 | 7.00 | 52.00 | 2.00 | 2.00 | 2.00 | $7M for Exclusive Test | ||||||||||
80 | Tag | CRE to oppose CL; royalty reduced to CL rate | 7/2005 | Fennec Pharmaceuticals | GlaxoSmithKline | Top Pharma | FOIA | Deal | 123.00 | 15.00 | 3.00 | 15.00 | Development, Equity, License, Option | Phase I | Eniluracil for oncology ex-Europe & Africa and Exherin (ADH-1 targeting N-cadherin) WW option | Exclusive | Asia, Middle East, NAFTA, South America | Cancer | Broad Focus Cancer | Peptides, Synthetics | Small Molecule | 3.00 | 60.00 | 63.00 | 60.00 | 13.00 | 14.00 | 15.00 | 13-15% royalty if GSK exercises latest take-back; otherwise, 8-9% or 11-13% on earlier take-backs | $3M, $10M or $60M in milestones on GSK take-back, depending on stage ($15M by Adherex if no take-back) | ||||||||||
81 | Tag | Royalty reduced to CL rate, calculated separately for each Licensed Product | 7/2005 | Otsuka Pharmaceutical, Avanir Pharmaceuticals | AstraZeneca | Top Pharma | FOIA | Deal | 10.00 | 389.75 | 11.00 | 11.00 | Co-Promotion, License, Research, Termination | Preclinical, Discovery | AZD2479 reverse cholesterol transport (RCT) compounds | Exclusive | Worldwide | Cardiovascular | Broad Focus Cardiovascular, Hypercholesterolemia | Synthetics | Small Molecule | 9.75 | 0.25 | 110.00 | 70.00 | 199.75 | 190.00 | 5.00 | 5.00 | 5.00 | 14 FTEs yr1; 10-15 FTEs/yr for yrs 2-3 | ||||||||
82 | Tag | Royalty reduced to CL rate | 6/2005 | Bukwang Pharmaceuticals | Gilead, Pharmasset | Major Biotech, 2003-12 IPOs | FOIA | Deal | 6.00 | 30.00 | 14.00 | 14.00 | License | Phase III | Clevudine (L-FMAU) for chronic HBV in NAFTA, Europe, SA & Israel | Exclusive | Europe, Middle East, NAFTA, South America | Infectious-Viral | Hepatitis B | Synthetics | Small Molecule | 10.00 | 16.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14% royalty (12% if licensed to one of top 100 pharma companies by sales) | |||||||||||
83 | Tag | CRE to oppose CL; royalty reduced to CL rate | 6/2005 | Ligand, Metabasis Therapeutics | Merck | Top Pharma | FOIA | Deal | 5.00 | 75.80 | 10.00 | 10.00 | Co-Promotion, Development, License, Option, Research | Lead Molecule | AMP-activated protein kinase for metabolic diseases | Exclusive | Worldwide | Endocrinological & Metabolic | Diabetes, Obesity, Other Endocrinological & Metabolic | Screening, Synthetics | Combinatorial | 6.30 | 0.30 | 44.00 | 20.00 | 75.30 | 6.00 | 6.00 | 8.00 | ||||||||||
84 | Tag | Royalty reduced to Generic Competition rate (50% of base rate) | 12/2004 | Mitsubishi Tanabe Pharma | MediciNova | 2003-12 IPOs | FOIA | Deal | 0.50 | 15.25 | 12.00 | 12.00 | Co-Promotion, License | Preclinical | MN-246 (TT-138 Beta 3 agonist) for incontinence, and metabolic diseases ex-Japan, China & Asean | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Endocrinological & Metabolic, Genitourinary/Gynecologic | Diabetes, Incontinence, Obesity | Synthetics | Small Molecule | 12.75 | 13.25 | 2.00 | 6.00 | 8.00 | 9.00 | ||||||||||||
85 | Tag | Royalty reduced to 50% of CL rate | 11/2004 | Health Protection Agency | Emergent BioSolutions | FOIA | Deal | 3.00 | 3.00 | License | Recombinant toxin fragments for treatment of illness caused by C. botulinum toxin | Exclusive | Worldwide | Infectious-Bacterial | Broad Focus Infectious-Bacterial | 3.00 | 3.00 | 3.00 | |||||||||||||||||||||
86 | Tag | Royalty reduced to CL rate | 10/2004 | Kyorin Pharmaceutical | MediciNova | 2003-12 IPOs | FOIA | Deal | 0.20 | 5.70 | 12.00 | 12.00 | License | Phase II, Orphan Indication | Ketas (ibudilast) for multiple sclerosis ex-Japan, China, S Korea | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Central Nervous System | Multiple Sclerosis | Synthetics | Small Molecule | 5.50 | 5.70 | 6.00 | 8.00 | 10.00 | 12% max in US; 9% max in ROW | ||||||||||||
87 | Tag | Royalty reduced to CL rate | 9/2004 | Adhera Therapeutics | Merck | Top Pharma | FOIA | Deal | 5.00 | 376.00 | 16.00 | 16.00 | Co-Promotion, Development, License, Loan, Supply, Termination | Phase I | PYY3-36 (Peptide YY nasal spray) for prevention of obesity | Exclusive | Worldwide | Endocrinological & Metabolic | Obesity | Drug Delivery, Peptides | Nasal | 30.00 | 131.00 | 166.00 | 210.00 | 9.00 | 10.00 | 11.00 | up to $30M loan for expansion of production capacity | ||||||||||
88 | Tag | Royalty reduced to CL rate | 8/2004 | Euthymics Bioscience, DOV Pharmaceutical | Merck | Top Pharma | FOIA | Deal | 35.00 | 480.00 | 20.00 | 20.00 | Co-Promotion, Development, License, Termination | Phase I | DOV 21947 & 216303 for depression, anxiety and addiction | Exclusive | Worldwide | Psychiatric | Addiction, Anxiety, Depression & Mania | Synthetics | Small Molecule | 185.00 | 140.00 | 360.00 | 120.00 | 11.00 | 11.00 | 12.00 | |||||||||||
89 | Tag | Royalty reduced to CL rate | 7/2004 | Cleveland Clinic | Cleveland BioLabs | 2003-12 IPOs | SEC Full | Deal | 8.00 | 2.00 | 2.00 | Equity, License | Discovery | Differential modulation cell death / survival mechanisms of cancer cells | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Genomics, Screening | Gene Expression | 1.50 | 6.50 | 8.00 | 2.00 | 2.00 | 2.00 | $1.5M for biodefense uses | $6.5M for all other uses | ||||||||||||
90 | Tag | Royalty reduced to CL rate | 6/2004 | Alnylam | Merck | Top Pharma | FOIA | Deal | 3.00 | 33.50 | 50.00 | 15.00 | Co-Development, Co-Promotion, License, Research, Termination | Discovery | RNAi VEGF for ocular diseases | Exclusive | Worldwide | Ophthalmic | Broad Focus Ophthalmic | Oligonucleotides | RNAi | 0.49 | 30.50 | 33.50 | 11.00 | 12.00 | 13.00 | 50.00 | |||||||||||
91 | Tag | Royalty reduced to CL rate so long as CL sales exceed 25% of total sales in such country | 6/2004 | Nektar Therapeutics | Allergan, AbbVie, MAP Pharmaceuticals | Top Pharma, Mid Tier Pharma, 2003-12 IPOs | FOIA | Deal | 4.00 | 5.00 | 5.00 | License | Preclinical, Formulation | SEDS Inhalation technology for dihydroergotamine mesylate for migraine | Exclusive | Worldwide | Central Nervous System | Migraine | Drug Delivery | Nasal | 0.30 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | |||||||||||||
92 | Tag | Royalty reduced to CL rate, but no lower than Know-how rate (66% of base rate) | 5/2004 | Inovio Pharmaceuticals | Merck | Top Pharma | FOIA | Deal | 1.00 | 38.75 | 5.00 | 5.00 | License, Option, Research, Supply | Formulation, Device | MedPulser electroporation delivery of CEA or HER2/neu for DNA Vaccines for infection & oncology | Non-exclusive | Worldwide | Cancer, Infectious-Bacterial, Infectious-Viral | Broad Focus Cancer, Broad Focus Infectious-Bacterial, Broad Focus Infectious-Viral | Device, Drug Delivery | Transdermal | 0.25 | 17.00 | 20.75 | 38.75 | 3.00 | 4.00 | 5.00 | |||||||||||
93 | Tag | Royalty reduced to Generic Competition rate (50% of base rate) | 4/2004 | Mitsubishi Tanabe Pharma | MediciNova | 2003-12 IPOs | FOIA | Deal | 1.00 | 19.75 | 12.00 | 12.00 | Co-Promotion, License | Phase I | MN-305 (serotonin ra) for anxiety ex-Japan, China & Asean | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Psychiatric | Anxiety | Synthetics | Small Molecule | 11.75 | 12.75 | 7.00 | 7.00 | 9.00 | 11.00 | ||||||||||||
94 | Tag | Royalty reduced to CL rate | 3/2004 | Oncternal Therapeutics, GTx | Johnson & Johnson, Ortho Biotech | Top Pharma | FOIA | Deal | 6.00 | 127.00 | 18.00 | 18.00 | Co-Promotion, Development, License | Phase I | Andarine SARM (Selective Androgen Receptor Modulator) for cancer-induced cachexia | Exclusive | Worldwide | Cancer, Endocrinological & Metabolic | Broad Focus Cancer, Other Endocrinological & Metabolic | Synthetics | Small Molecule | 0.23 | 37.00 | 84.00 | 127.00 | 9.00 | 11.00 | 13.00 | 25.00 | 25% Additional Royalty on sales by GTx to Urologists in the US from Co-promotion | |||||||||
95 | Tag | Royalty reduced to CL rate | 2/2004 | Kissei Pharmaceutical | MediciNova | 2003-12 IPOs | FOIA | Deal | 18.00 | 8.00 | 8.00 | Co-Promotion, License, Supply | Phase II | MN-221 (KUR-1246) to treat premature labor ex-Japan | Exclusive | Africa, Asia, Europe, Middle East, NAFTA, South America | Genitourinary/Gynecologic | Other Genitourinary/Gynecologic | Synthetics | Small Molecule | 18.00 | 18.00 | 8.00 | 8.00 | 8.00 | ||||||||||||||
96 | Tag | CRE to oppose CL; royalty reduced to CL rate | 12/2003 | Ligand, Metabasis Therapeutics | Merck | Top Pharma | FOIA | Deal | 0.50 | 62.88 | 9.00 | 9.00 | License, Option, Research | Discovery, Formulation | HepDirect prodrug technology for HCV compounds | Exclusive | Worldwide | Infectious-Viral | Hepatitis C | Drug Delivery, Screening, Synthetics | Other, Small Molecule | 1.38 | 0.28 | 25.00 | 36.00 | 62.88 | 7.00 | 7.00 | 7.00 | ||||||||||
97 | Tag | Royalty reduced to CL rate | 11/2003 | AVEO Pharmaceuticals | Merck | Top Pharma | FOIA | Deal | 9.25 | 62.80 | 7.00 | 5.00 | 7.00 | Equity, License, Research | Discovery | Tumor maintenance genes as small molecule oncology targets | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Genomics, Screening | Gene Expression | 5.00 | 6.00 | 0.30 | 42.55 | 62.80 | 5.00 | 6.00 | 6.00 | $5M eq at time of 4/05 restated agmt | ||||||||
98 | Tag | Royalty reduced to CL rate | 11/2003 | Ligand, Neurogen | Merck | Top Pharma | FOIA | Deal | 22.00 | 344.80 | 12.00 | 15.00 | 12.00 | Equity, License, Research, Termination | Lead Molecule, Discovery | Novel modulators of Vanilloid Receptors (VR1) for Pain & Incontinence | Exclusive | Worldwide | Central Nervous System, Genitourinary/Gynecologic | Incontinence, Pain | Recombinant DNA | 15.00 | 9.80 | 0.28 | 118.00 | 155.00 | 319.80 | 25.00 | 10.00 | 10.00 | 11.00 | ||||||||
99 | Tag | Royalty reduced to 50% of CL rate | 10/2003 | Abgenix | AstraZeneca | Top Pharma | FOIA | Deal | 151.00 | 12.00 | 100.00 | 12.00 | Co-Development, Equity, License, Option, Research | Discovery | Fully human monoclonal antibodies to UPAR and add'l targets for cancer | Exclusive | Worldwide | Cancer | Broad Focus Cancer | Monoclonals | Human Abs | 100.00 | 60.00 | 51.00 | 211.00 | 8.00 | 9.00 | 11.00 | 18.00 | 8-12% for Proprietary ABX Antigens; 6-10% for Non-Proprietary | $100M in preferred, convertible at $30/Sh | |||||||||
100 | Tag | Royalty reduced to Generic Product rate (50% of base rate if 30%+ unit share, 80% of base if 15-30% units) | 10/2003 | Anesiva | Bristol-Myers Squibb | Top Pharma | FOIA | Deal | 25.00 | 570.00 | 50.00 | 20.00 | Co-Development, Co-Promotion, Equity, License | Phase III | E2F Decoy transcription factor for restenosis & atherosclerosis | Exclusive | Worldwide | Cardiovascular | Atherosclerosis/Coronary Artery Disease, Restenosis | Transcription Factors | 20.00 | 108.50 | 96.50 | 250.00 | 320.00 | 14.00 | 15.00 | 17.00 | 50.00 |